Volgen
Anthony P Conley, MD
Anthony P Conley, MD
Associate Professor; Department of Sarcoma Medical Oncology; University of Texas MD Anderson Cancer
Geverifieerd e-mailadres voor mdanderson.org
Titel
Geciteerd door
Geciteerd door
Jaar
Immuno-genomic landscape of osteosarcoma
CC Wu, HC Beird, J Andrew Livingston, S Advani, A Mitra, S Cao, ...
Nature communications 11 (1), 1008, 2020
2062020
Cause of death in patients with lower‐risk myelodysplastic syndrome
F Dayyani, AP Conley, SS Strom, W Stevenson, JE Cortes, G Borthakur, ...
Cancer 116 (9), 2174-2179, 2010
2042010
Epidemiology and therapies for metastatic sarcoma
EK Amankwah, AP Conley, DR Reed
Clinical epidemiology, 147-162, 2013
1752013
Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials
R Groisberg, DS Hong, A Behrang, K Hess, F Janku, S Piha-Paul, ...
Journal for immunotherapy of cancer 5, 1-8, 2017
1482017
The role of chemotherapy in advanced solitary fibrous tumors: a retrospective analysis
MS Park, V Ravi, A Conley, SR Patel, JC Trent, DC Lev, AJ Lazar, ...
Clinical sarcoma research 3, 1-7, 2013
1222013
Clinical characteristics and outcomes for solitary fibrous tumor (SFT): a single center experience
N DeVito, E Henderson, G Han, D Reed, MM Bui, R Lavey, L Robinson, ...
PLoS One 10 (10), e0140362, 2015
1102015
Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor
WL Wang, A Conley, D Reynoso, L Nolden, AJ Lazar, S George, JC Trent
Cancer chemotherapy and pharmacology 67, 15-24, 2011
982011
Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial
N Somaiah, AP Conley, ER Parra, H Lin, B Amini, LS Soto, R Salazar, ...
The Lancet Oncology 23 (9), 1156-1166, 2022
962022
Uterine adenosarcoma: a review
MJ Nathenson, V Ravi, N Fleming, WL Wang, A Conley
Current oncology reports 18, 1-17, 2016
942016
Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes
J Roszik, WL Wang, JA Livingston, CL Roland, V Ravi, C Yee, P Hwu, ...
Clinical Sarcoma Research 7, 1-7, 2017
852017
Role of chemotherapy in dedifferentiated liposarcoma of the retroperitoneum: defining the benefit and challenges of the standard
JA Livingston, D Bugano, A Barbo, H Lin, JE Madewell, WL Wang, ...
Scientific reports 7 (1), 11836, 2017
812017
Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas
R Groisberg, DS Hong, V Holla, F Janku, S Piha-Paul, V Ravi, R Benjamin, ...
Oncotarget 8 (24), 39254, 2017
772017
Casting a wider net: Immunosurveillance by nonclassical MHC molecules
MP D’Souza, E Adams, JD Altman, ME Birnbaum, C Boggiano, G Casorati, ...
PLoS pathogens 15 (2), e1007567, 2019
712019
Atezolizumab for advanced alveolar soft part sarcoma
AP Chen, E Sharon, G O’Sullivan-Coyne, N Moore, JC Foster, JS Hu, ...
New England Journal of Medicine 389 (10), 911-921, 2023
612023
Immunotherapy: a new (and old) approach to treatment of soft tissue and bone sarcomas
MJ Nathenson, AP Conley, E Sausville
The oncologist 23 (1), 71-83, 2018
612018
Progressive and reversible conduction disease with checkpoint inhibitors
N Reddy, R Moudgil, JC Lopez-Mattei, K Karimzad, EN Mouhayar, ...
Canadian Journal of Cardiology 33 (10), 1335. e13-1335. e15, 2017
572017
Comprehensive characterization of malignant phyllodes tumor by whole genomic and proteomic analysis: biological implications for targeted therapy opportunities
DLF Jardim, A Conley, V Subbiah
Orphanet journal of rare diseases 8, 1-8, 2013
572013
Phase II study of atezolizumab in advanced alveolar soft part sarcoma (ASPS)
AR Naqash, GH O’Sullivan Coyne, N Moore, E Sharon, N Takebe, ...
J Clin Oncol 39 (15_suppl), 11519, 2021
492021
Outcome of first‐line systemic treatment for unresectable conventional, dedifferentiated, mesenchymal, and clear cell chondrosarcoma
A van Maldegem, AP Conley, P Rutkowski, SR Patel, I Lugowska, ...
The Oncologist 24 (1), 110-116, 2019
492019
Cytokines produced by dendritic cells administered intratumorally correlate with clinical outcome in patients with diverse cancers
V Subbiah, R Murthy, DS Hong, RM Prins, C Hosing, K Hendricks, D Kolli, ...
Clinical Cancer Research 24 (16), 3845-3856, 2018
452018
Het systeem kan de bewerking nu niet uitvoeren. Probeer het later opnieuw.
Artikelen 1–20